| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK6 |
| Uniprot No | P42773 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-168aa |
| 氨基酸序列 | MAEPWGNELA SAAARGDLEQ LTSLLQNNVN VNAQNGFGRT ALQVMKLGNP EIARRLLLRG ANPDLKDRTG FAVIHDAARA GFLDTLQTLL EFQADVNIED NEGNLPLHLA AKEGHLRVVE FLVKHTASNV GHRNHKGDTA CDLARLYGRN EVVSLMQANG AGGATNLQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CDK6重组蛋白的相关文献概览：
---
1. **文献名称**：*Structural basis of CDK6 activation by viral cyclins and p27KIP1 inhibition*
**作者**：Mathias, C. et al.
**摘要**：通过X射线晶体学解析了CDK6与病毒Cyclin(如KSHV Cyclin)及抑制剂p27KIP1的复合物结构，阐明了重组CDK6的激活机制和抑制剂的结合位点，为靶向CDK6的癌症治疗提供结构基础。
---
2. **文献名称**：*CDK6 kinase activity is required for thymocyte development*
**作者**：Kollmann, S. et al.
**摘要**：利用重组CDK6蛋白进行体外激酶实验，证明其在T细胞发育中的关键作用，研究揭示了CDK6特异性底物及其在造血系统中的功能调控网络。
---
3. **文献名称**：*Recombinant CDK6/Cyclin D1 complex production and inhibitor screening*
**作者**：Johnson, D.G. & Walker, C.L.
**摘要**：开发了高效表达和纯化CDK6/Cyclin D1重组蛋白复合物的方法，并基于此建立高通量抑制剂筛选平台，筛选出多个潜在小分子抑制剂，用于乳腺癌靶向治疗研究。
---
**备注**：以上文献为示例性内容，实际引用时需核对具体论文信息。建议通过PubMed或Web of Science以关键词“CDK6 recombinant protein”或“CDK6 kinase activity”检索最新研究。
**Background of CDK6 Recombinant Protein**
CDK6 (cyclin-dependent kinase 6) is a serine/threonine kinase belonging to the CDK family, which plays a pivotal role in regulating the cell cycle transition from the G1 phase to the S phase. It functions by forming a complex with D-type cyclins (e.g., cyclin D1. D2. or D3), enabling phosphorylation of the retinoblastoma protein (Rb). This phosphorylation event releases E2F transcription factors, initiating DNA replication and promoting cell cycle progression. Beyond its canonical role in cell cycle control, CDK6 is implicated in transcriptional regulation, differentiation, and hematopoietic development, with tissue-specific expression patterns observed in certain cancers and immune cells.
Recombinant CDK6 protein is engineered through molecular cloning, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Purification methods (e.g., affinity chromatography) yield high-purity, bioactive CDK6 for *in vitro* studies. This recombinant tool is widely utilized to investigate CDK6-cyclin interactions, kinase activity assays, and drug screening for inhibitors targeting CDK6-driven malignancies. Dysregulation of CDK6. such as overexpression or mutations, is linked to cancers (e.g., leukemia, breast cancer) and metabolic disorders, making it a therapeutic target. Small-molecule CDK4/6 inhibitors (e.g., palbociclib) are FDA-approved for cancer treatment, underscoring the clinical relevance of studying CDK6 mechanisms.
Additionally, recombinant CDK6 aids in structural biology studies (e.g., crystallography) to map binding sites and optimize drug design. Its role in non-cancer contexts, such as inflammation and stem cell maintenance, further expands its research applications. Overall, CDK6 recombinant protein serves as a critical reagent for unraveling cellular proliferation pathways and advancing targeted therapies.
×
